Company / Net Debt per Share
Apellis Pharmaceuticals, Inc. Net Debt per Share History
FY2017-FY2023 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Net Debt per Share
-$2.33
FY2023
5-year range
-$4.71 / -$2.33
FY2019-FY2023
Trend
+50.5%
vs FY2022
Sector context
#69 of 82
Health Care
What the data says
Apellis Pharmaceuticals, Inc.'s net debt per share of $-2.33 is lower than 84% of companies in the Health Care sector (FY2023). Increased from $-10.72 to $-2.33 over the past 6 years.
Based on SEC 10-K filings.
-2.33 in FY2023.
Increased from $-10.72 to $-2.33 over the past 6 years.
Health Care sector context is included.
Net Debt per Share over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Top 16% in Health CareTop 16% of 82This company -$2.33 Sector average $13.70
▼
-117.0% below sector average
Key checks
Key Insights
- In FY2023, net debt per share increased 50.5% year-over-year.
- Ranks #69 out of 82 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score -0.60 (distress zone, below 1.8 threshold)
- Negative profit margin: -25.3%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Net Debt per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | -$2.33 | +50.5% |
| FY2022 | -$4.71 | - |
| FY2021 | - | - |
| FY2020 | - | - |
| FY2019 | - | - |
| FY2018 | - | - |
| FY2017 | -$10.72 | - |
| FY2016 | - | - |
As of FY2023 · SEC 10-K · Updated Feb 28, 2026